A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant

Background: To date, the only potential curative treatment for multiple myeloma (MM) remains allogeneic (allo) hematopoietic cell transplant (HCT), although, most patients will eventually relapse. In relapsed patients, donor lymphocyte infusions (DLIs) have been reported to control disease, but the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Richard LeBlanc, Stéphanie Thiant, Rafik Terra, Imran Ahmad, Jean-Sébastien Claveau, Nadia Bambace, Léa Bernard, Sandra Cohen, Jean-Sébastien Delisle, Silvy Lachance, Thomas Kiss, Denis-Claude Roy, Guy Sauvageau, Jean Roy
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Current Oncology
Subjects:	allogeneic hematopoietic cell transplant donor lymphocyte infusion minimal measurable disease multiple myeloma
Online Access:	https://www.mdpi.com/1718-7729/31/11/535
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant

Similar Items